Core Viewpoint - Fortrea, a leading global contract research organization, is set to present at the J.P. Morgan Annual Healthcare Conference on January 13, 2026, at 11:15 am PST, highlighting its role in the life sciences industry [1]. Company Overview - Fortrea (Nasdaq: FTRE) specializes in providing clinical development solutions to the life sciences sector, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies to enhance healthcare innovation [3]. - The company offers a range of services including phase I-IV clinical trial management, clinical pharmacology, and consulting, leveraging over 30 years of experience across more than 20 therapeutic areas [3]. - Fortrea operates in approximately 100 countries, emphasizing a strong investigator site network and a commitment to delivering agile solutions to its clients [3].

DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference in January: J.P. Morgan Annual Healthcare Conference (San Francisco)Date:Tuesday, January 13, 2025Time:5:15 pm PSTFormat:Presentation and Q&A The live webcast and replay can be accessed through the “Events” section of Fortrea’s Inves ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund’s Investor Class fund ARTQX returned 0.97%, Advisor Class fund APDQX posted a return of 0.98%, and Institutional Class fund APHQX returned 0.97%, compared to a 6.18% return for the Russell Midcap Value Index. Equity markets continued their rally in the third quarter as investors overlooked tariff concerns, driv ...

Core Insights - Charles River Laboratories International, Inc. (CRL) is a leading American contract research organization (CRO) with a market cap of $9.5 billion, serving various sectors including pharmaceuticals and biotechnology [1] - CRL is categorized as a mid-cap stock, benefiting from strong competitive advantages such as end-to-end preclinical drug development capabilities and long-standing client relationships [2] - The stock has shown significant short-term performance, gaining 30.2% over the past three months, outperforming the Dow Jones Industrial Average [3] Performance Metrics - CRL reached a 52-week high of $200.58, but on a year-to-date basis, it is up only 7.3%, lagging behind the Dow's 13.8% rise in 2025 [3][4] - The stock has maintained a position above its 50-day and 200-day moving averages since late September, indicating a strengthening technical uptrend [4] - Following an upgrade from JPMorgan Chase & Co., CRL shares gained over 2%, with the price target raised to $190, reflecting optimism about the company's fundamentals [5] Competitive Position - Compared to its peer Labcorp Holdings Inc., CRL has underperformed, with Labcorp showing a 14.8% increase year-to-date and 13.5% over the past 52 weeks [6]

Wasatch Global Investors, an asset management company, released its third-quarter 2025 “Wasatch Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. US small-cap equities rallied strongly in the third quarter. The Fed Reserve’s interest rate cut supported the rally. However, the fund-Investor Class struggled to keep up with the rally and ended the period down -3.17% vs. 12.19% gain for the Russell 2000 Growth Index. In addition, please check the fund’s top five holdings t ...

Core Insights - Inotiv, Inc. has announced a strategic collaboration with VUGENE to enhance AI-assisted drug discovery and improve data-driven insights across the drug development continuum [1][2]. Company Overview - Inotiv, Inc. is a leading Contract Research Organization (CRO) that specializes in nonclinical and analytical drug discovery and development services, as well as research models and related products [1][4]. - The company focuses on increasing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market [4]. Collaboration Details - The partnership will integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, facilitating more efficient analysis of complex biological data [2][3]. - This collaboration aims to enhance Inotiv's capabilities in interpreting various molecular datasets, ultimately improving predictions of drug efficacy and safety during early-stage research [2][3]. Strategic Goals - The collaboration is expected to enable clients to make faster and more informed decisions by leveraging VUGENE's AI-enabled bioinformatics platform [3]. - The partnership represents an opportunity for VUGENE to expand the application of its computational technologies in real-world research environments [3][5]. Technological Integration - VUGENE's platform integrates biological data from multiple sources, including (epi)genomics, transcriptomics, proteomics, and metabolomics, to elucidate disease mechanisms and therapeutic modes of action [5].

Core Insights - Polen Capital's "Polen International Growth Strategy" reported a return of -4.23% gross and -4.53% net of fees in Q3 2025, underperforming the MSCI ACWI (ex-USA) which gained 6.89% [1] - The strategy's concentrated quality investing approach did not yield expected results during the quarter [1] Company Performance - ICON Public Limited Company (NASDAQ:ICLR) was highlighted as a top contributor to the portfolio's performance, with a one-month return of 11.43% despite a 15.68% decline over the past 52 weeks [2][3] - ICON's stock closed at $182.10 on December 08, 2025, with a market capitalization of $14.162 billion [2] - The company reported Q3 2025 revenue of $2.043 billion, reflecting a year-on-year increase of 0.6% [4] Investment Outlook - Polen Capital believes that ICON is positioned for recovery and steady, low double-digit EPS growth, viewing it as a best-in-class operator in its sector [3] - Despite ICON's potential, the analysis suggests that certain AI stocks may offer greater upside potential with less downside risk [4]

PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global contract research organization (CRO), today announced a strategic collaboration agreement between the two companies. This partnership aims to streamline development, accelerate timelines and bring advanced therapies to patients faster. This collaboration represents a forward-looking model for how CDMOs and CROs can ...

– Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million– Fiscal 2025 revenue increased 4.5% to $513.0 million– Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million– Fiscal 2025 operating loss decreased 64.2% to $30.9 million– Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and deve ...

Core Insights - Fortrea, a leading global contract research organization (CRO), is actively participating in key healthcare conferences in December 2025, showcasing its commitment to engaging with investors and stakeholders [1][2]. Company Overview - Fortrea (Nasdaq: FTRE) provides clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies to accelerate healthcare innovation [3]. - The company offers a range of services including phase I-IV clinical trial management, clinical pharmacology, and consulting, leveraging over three decades of experience across more than 20 therapeutic areas [3]. - Fortrea operates in approximately 100 countries, emphasizing a diverse and talented team to deliver agile solutions globally [3].